Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise

Inhibiting menin, a macromolecule that supports leukemia maturation and is already targeted to dainty immoderate forms of leukemia, besides holds committedness for treating myeloproliferative neoplasms. A caller survey from scientists astatine St. Jude Children's Research Hospital showed that inhibiting menin importantly extended endurance and reversed aggregate illness features successful preclinical models. The findings were published contiguous successful Cancer Cell.